Cemsidomide

Cemsidomide is an investigational, orally bioavailable molecular glue degrader (MonoDAC® degrader) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that support the potential for durable outcomes.

Opportunity for Targeted Protein Degradation

IKZF1/3 are transcription factors required for cancer cell growth and survival in multiple myeloma. However, transcription factors do not have an active site binding pocket; this means inhibitors cannot target these important proteins. Rather, degraders are the only therapeutic approach. Today, approved IKZF1/3 degraders (lenalidomide and pomalidomide) are widely used in multiple myeloma treatment, but there remains a high unmet medical need for therapies to treat relapsed/refractory multiple myeloma.

Scientific Presentations and Publications

Population Pharmacokinetics and Exposure-response Analysis of Cemsidomide in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin’s Lymphoma

Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Initial Results of a Phase 1 First-in-Human Study of CFT7455 (Cemsidomide), a Novel MonoDAC® Degrader, with Dexamethasone (Dex) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, in Patients with Non-Hodgkin’s Lymphoma

CFT7455, a novel IKZF1/3 degrader, enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses

CFT7455: A novel IKZF1/3 degrader, demonstrates potent anti-tumor activity in peripheral and CNS models of non-Hodgkin’s lymphoma as a single agent or in combination with clinically approved agents

The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1/3 for the Treatment of Relapsed/Refractory Multiple Myeloma

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

CFT7455: A novel, IKZF1/3 Degrader That Demonstrates Potent Tumor Regression in a Spectrum of Non-Hodgkin Lymphoma Xenograft Models

CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models